Home » Medical Devices » Deep Brain Stimulation Devices Market

Deep Brain Stimulation Devices Market By Modality (Subthalamic Nucleus (STN) DBS, Globus Pallidus Interna (GPi) DBS, Thalamus (Vim) DBS), By Application (Parkinson’s Disease, Epilepsy, Obsessive Compulsive Disorder (OCD), Dystonia, Essential Tremors) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Summary
Table Of Content

Industry Outlook

Across the world, deep brain stimulation (DBS) is being used for treating pain and movement disorders such as tremors and Parkinson’s disease. Some other recognized conditions for deep brain stimulation include epilepsy, obsessive compulsive disorders and dystonia. There are other conditions such as Tourette syndrome, bipolar disorder, auditory disorders, tinnitus and others, which are investigational for DBS therapy.

Particularly about DBS for psychiatric disorders, the subcommittee of the World Society for Stereotactic and Functional Neurosurgery had published consensus on Guidelines for Stereotactic Neurosurgery for Psychiatric Disorders. This suggested that DBS for psychiatric disorders is investigational and the procedures need to be done based on scientific protocol, by multidisciplinary team and with regulatory and ethical oversight. Over a million patients have been treated with DBS worldwide and the potential patient population is still growing. Furthermore, as there is no inaccessible area in the brain, the limit as to where the electrodes can be applied is nonexistent.

Therefore, there is no limit to the diseases treatable with DBS. This in turn, has raised certain ethical issues, particularly with respect to neuroethics concerning alteration of central nervous system circuitry. Hence, the ethical front of the application of DBS should be determined on the basis of the current social philosophy.

Market Synopsis

Subthalamic Nucleus to Remain the Commonly Used Target for DBS

DBS of the brain thalamus was first approved by the USFDA for tremors in 1997. Afterwards, DBS for subthalamic nucleus (STN) and globus pallidus interna (GPi) for Parkinson’s disease were approved in 2002 and 2003 respectively. The GPi DBS gained further approval for dystonia treatment under humanitarian device exemption in 2003. At present GPi and STN are the prominent viable targets for DBS. The choice of site mainly focuses on the type of motor and non-motor symptoms, being the key determinants of quality of life. The STN is the most commonly used target for DBS for the treatment of Parkinson’s disease.

The STN is a prime location in the basal ganglia circuits therefore serve as a major target for cortical afferents and receive inputs from other parts of the basal ganglia. About half of the DBS treatments for Parkinson’s disease are performed on the STN target. STN DBS offers very effective therapy for certain motor symptoms of Parkinson’s disease such as stiffness, tremors and bradykinesia, therefore gaining high popularity in the market. on the other hand, dystonia patients often opt for GPi DBS, as it offers significant remission of painful cramping and posturing. GPi DNS is also effective for relieving motor symptoms of Parkinson’s disease.

Proven Benefits and Efficacy of DBS in Parkinson’s Disease to Remain the Mainstay for Market Growth

Following the success of DBS in treating Parkinson’s disease, DBS surgery has revamped the interest in neurological management of psychiatric disorders. Based on this DBS received FDA approval for treatment of obsessive compulsive disorder on humanitarian device exemption status. Other conditions in which DBS therapy is shown to have benefits include epilepsy, neuropathic pain, post-stroke pain, depression, cluster headache, multiple sclerosis tremors and so on.

DBS surgery is also being investigated for addictions, traumatic brain injury, eating disorders, and post-traumatic stress disorders. At present DBS application for Parkinson’s disease treatment dominates the global market. Proven clinical evidence and early bird advantage are the key factors assisting the prominence of DBS for Parkinson’s disease segment. DBS has gradually become the procedure of choice for Parkinson’s disease treatment as it does not involve destruction of the brain tissue, adjustable and can be reversed. GPi and STN are the preferred targets for DBS for Parkinson’s disease. However, reports suggest that Vim can also be used in cases of primary symptoms of tremors.

North America to Dominate the Global Market through the Forecast Period due to Significantly Large Patient Pool

Currently, North America leads the global deep brain stimulation devices market. Greater prevalence of neurological conditions, faster diagnosis and adoption rates, and better reimbursements mainly contribute to the dominance of North America market. Europe is estimated to be the second in lead on the global front. Intensive marketing of DBS and rapid adoption of novel technologies in the region facilitates the prime position of North America. Additionally, Asia Pacific will advance at the fastest growth rate during the forecast period. Improving government policies for attracting players from the developed regions, evolving reimbursements, growing awareness and skills, and proliferating medical tourism industry in the region facilitate the progress of Asia Pacific market.

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This research report presents the analysis of each considered segment for the period from 2016 to 2026, having 2017 as the base year for estimations. Compounded annual growth rates (CAGRs) for each segment are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report on global deep brain stimulation devices market offers both quantitative information of the industry in terms of market size and forecast for the considered segments and prevalent market dynamics. The qualitative information incorporated in the report include a brief about the market dynamics such as the market drivers, challenges and opportunities currently prevalent in the industry. For the purpose of this study, the global deep brain stimulation devices market is studies for modalities, applications and geography.

By Modality (2016–2026; US$ Mn)

Subthalamic Nucleus (STN) DBS
Globus Pallidus Interna (GPi) DBS
Thalamus (Vim) DBS

By Application (2016–2026; US$ Mn)

Parkinson’s Disease
Epilepsy
Obsessive Compulsive Disorder (OCD)
Dystonia
Essential Tremors

Geography Segment (2016–2026; US$ Mn)

North America
- The U.S.
- Canada
Europe
- The U.K.
- Germany
- Rest of Europe
Asia Pacific (APAC)
- China
- Japan
- Rest of APAC
Latin America (LATAM)
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa (MEA)
- GCC
- Rest of Middle East and Africa

The report also includes competitive analysis of the prominent players in the global deep brain stimulation devices market. The profiles of such players are also assessed in the study based on their business overview, product portfolio, financial information, and key developments. The prime players operating in the global deep brain stimulation devices market are Medtronic Plc, Boston Scientific Corporation, Abbott (St. Jude Medical, Inc.), Aleva Neurotherapeutics SA, NeuroPace, Inc., PINS Medical Co., Ltd.

Key questions answered in this report

What is the current position of the global deep brain stimulation devices market?
How the global market will advance through the forecast period from 2018 to 2026?
What are the currently prevalent market dynamics and how are they defining the trends?
Which the key market opportunities can be tapped for achieving market success?
What are the key strategies adopted by major market players?
How is the market turf for new entrants?
Which region will witness the most prominent changes during the forecast period?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I – Secondary Research
1.4.2. Phase II – Primary Research
1.4.3. Phase III – Expert Panel Review
1.4.4. Assumptions
1.5. Market Segmentation

Chapter 2. Executive Summary
2.1. Global DBSD Market Portraiture
2.2. Global DBSD Market, by Modality, 2017 (US$ Mn)
2.3. Global DBSD Market, by Application, 2017 (US$ Mn)
2.4. Global DBSD Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Deep Brain Stimulation Devices (DBSD) Market: Dynamics and Future Outlook
3.1. Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global DBSD Market, by Key Players, 2017

Chapter 4. Global Deep Brain Stimulation Devices (DBSD) Market, by Modality, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Subthalamic Nucleus (STN) DBS
4.3. Globus Pallidus Interna (GPi) DBS
4.4. Thalamus (Vim) DBS

Chapter 5. Global Deep Brain Stimulation Devices (DBSD) Market, by Application, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Parkinson’s Disease
5.3. Epilepsy
5.4. Obsessive Compulsive Disorder (OCD)
5.5. Dystonia
5.6. Essential Tremors

Chapter 6. Global Deep Brain Stimulation Devices (DBSD) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.1.1. North America DBSD Market, 2016-2026 (US$ Mn)
6.1.2. North America DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
6.1.3. North America DBSD Market, by Application, 2016 – 2026 (US$ Mn)
6.1.4. North America DBSD Market, by Country, 2016 – 2026 (US$ Mn)
6.1.4.1. U.S.
6.1.4.2. Canada
6.2. Europe DBSD Market, 2016 – 2026 (US$ Mn)
6.2.1. Europe DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
6.2.2. Europe DBSD Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. Europe DBSD Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific DBSD Market, 2016 – 2026 (US$ Mn)
6.3.1. Asia Pacific DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
6.3.2. Asia Pacific DBSD Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Asia Pacific DBSD Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America DBSD Market, 2016 – 2026 (US$ Mn)
6.4.1. Latin America DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
6.4.2. Latin America DBSD Market, by Application, 2016 – 2026 (US$ Mn)
6.4.3. Latin America DBSD Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa DBSD Market, 2016 – 2026 (US$ Mn)
6.5.1. Middle East & Africa DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
6.5.2. Middle East & Africa DBSD Market, by Application, 2016 – 2026 (US$ Mn)
6.5.3. Middle East & Africa DBSD Market, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa

Chapter 7. Company Profiles
7.1. Medtronic Plc
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Boston Scientific Corporation
7.3. Abbott (St. Jude Medical, Inc.)
7.4. Aleva Neurotherapeutics SA
7.5. NeuroPace, Inc.
7.6. PINS Medical Co., Ltd.

List of Figures

FIG 1. Deep Brain Stimulation Devices (DBSD) Market: Research Methodology
FIG 2. DBSD Market Segmentation
FIG 3. Global DBSD Market, by Modality, 2017 (US$ Mn)
FIG 4. Global DBSD Market, by Application, 2017 (US$ Mn)
FIG 5. Global DBSD Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global DBSD Market, by Key Players, 2017
FIG 8. Global Subthalamic Nucleus (STN) DBS Devices Market, 2016-2026(US$ Mn)
FIG 9. Global Globus Pallidus Interna (GPi) DBS Devices Market, 2016-2026 (US$ Mn)
FIG 10. Global Thalamus (Vim) DBS Devices Market, 2016-2026 (US$ Mn)
FIG 11. Global DBSD Market for Parkinson’s Disease, 2016-2026 (US$ Mn)
FIG 12. Global DBSD Market for Epilepsy, 2016-2026 (US$ Mn)
FIG 13. Global DBSD Market for Obsessive Compulsive Disorder (OCD), 2016-2026 (US$ Mn)
FIG 14. Global DBSD Market for Dystonia, 2016-2026 (US$ Mn)
FIG 15. Global DBSD Market for Essential Tremors, 2016-2026 (US$ Mn)
FIG 16. U.S. DBSD Market, 2016-2026 (US$ Mn)
FIG 17. Canada DBSD Market, 2016-2026 (US$ Mn)
FIG 18. U.K. DBSD Market, 2016-2026 (US$ Mn)
FIG 19. Germany DBSD Market, 2016-2026 (US$ Mn)
FIG 20. Rest of Europe DBSD Market, 2016-2026 (US$ Mn)
FIG 21. China DBSD Market, 2016-2026 (US$ Mn)
FIG 22. Japan DBSD Market, 2016-2026 (US$ Mn)
FIG 23. Rest of Asia Pacific DBSD Market, 2016-2026 (US$ Mn)
FIG 24. Brazil DBSD Market, 2016-2026 (US$ Mn)
FIG 25. Mexico DBSD Market, 2016-2026 (US$ Mn)
FIG 26. Rest of Latin America DBSD Market, 2016-2026 (US$ Mn)
FIG 27. GCC DBSD Market, 2016-2026 (US$ Mn)
FIG 28. Rest of Middle East and Africa DBSD Market, 2016-2026 (US$ Mn)

List of Tables

TABLE 1 Global Deep Brain Stimulation Devices (DBSD) Market Portraiture
TABLE 2 Global DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
TABLE 3 Global DBSD Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 4 North America DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
TABLE 5 North America DBSD Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 6 North America DBSD Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 7 Europe DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
TABLE 8 Europe DBSD Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 9 Europe DBSD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific DBSD Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific DBSD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 13 Latin America DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America DBSD Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America DBSD Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Middle East and Africa DBSD Market, by Modality, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East and Africa DBSD Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East and Africa DBSD Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 19 Medtronic Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Boston Scientific Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Abbott (St. Jude Medical, Inc.): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Aleva Neurotherapeutics SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 NeuroPace, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 PINS Medical Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions:

What is the size of Deep Brain Stimulation Devices Market?

The market for Deep Brain Stimulation Devices Market is expected to reach US$ XXMn by 2026.

What is the Deep Brain Stimulation Devices Market CAGR?

The Deep Brain Stimulation Devices Market is expected to see significant CAGR growth over the coming years, at 5.8%.

What is the Forecast period considered for Deep Brain Stimulation Devices Market?

The report is forecasted from 2018-2026.

What is the base year considered for Deep Brain Stimulation Devices Market?

The base year of this report is 2017.

Who are the major players in this market?

Raytheon Company, Northrop Grumman Corporation, Frequentis AG, Searidge Technologies Inc., NavAero Inc., Becker Avionics Inc., Lockheed Martin Corporation, Indra Sistemas SA, Advanced Navigation & Positioning Corporation Inc. are some of the major players in the global market.

Purchase Options

Single User

$3699

Multi User

$4699

Enterprise

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –